Recently, FTSE Russell has updated its semi-annual adjustment list for the FTSE Global Equity Index Series for September. In the Hong Kong stock segment, Chifeng Gold (06693) and Laopu Gold (06181) have been included in the FTSE China Large Cap Index, while 11 Hong Kong stocks including SF Intra-city (09699), RoboSense (02498), Fourth Paradigm (06682), and Heyo-B (02256) have been included in the FTSE China Small Cap Index. These adjustments will officially take effect after market close on September 19th.

As one of the global leaders in the index industry, FTSE Russell has long provided innovative benchmarks, analytics, and data solutions for global investors. Currently, approximately $20 trillion in global assets are benchmarked to FTSE Russell indices, with their products widely adopted by institutional and individual investors worldwide.

The FTSE Global Equity Index Series divides constituent stocks into four market capitalization tiers based on free-float market capitalization (market value after excluding strategic holdings, restricted shares, and other non-freely tradable portions), including large-cap, mid-cap, small-cap, and micro-cap stocks.

In this adjustment, the FTSE China Large Cap Index, which concentrates companies with large market capitalization, high liquidity, and industry leadership, has included 9 Hong Kong stocks. Chifeng Gold and Laopu Gold are first-time inclusions, while 3SBIO (01530), China Ruiyi (00136), Meitu (01357), NetEase Cloud Music (09899), RemeGen (09995), Shanghai Fudan (01385), and Sunshine Insurance (06963) are all scale adjustments, upgraded from mid-cap or small-cap categories.

For mid-cap stocks, 1 Hong Kong stock was included: Xinyi Solar (00968), downgraded from large-cap.

Small-cap inclusions comprise 14 Hong Kong stocks, with 11 new additions including Heyo-B, Fourth Paradigm, SF Intra-city, Health Road (02587), 9F Inc (09636), RoboSense, Yatsen (02145), Wan Kwo Gold (03939), Weilong (09985), XtalPi (02228), and Yixin Group (02858). IASO Bio-B (02171), Zai Lab (01952), and K. Wah International (00173) represent domicile corrections, changing from Hong Kong region to China region.

From this FTSE Russell index series constituent adjustment, newly selected stocks demonstrate two particularly prominent common characteristics: first, most have recorded significant gains year-to-date, performing notably better than the broader market and showing outstanding periodic performance; second, these companies mostly belong to sectors with clear growth attributes and vibrant industry dynamics, reflecting the index's precise identification of high-growth sectors and forward-looking positioning.

In terms of market performance, all 9 stocks included in this adjustment have achieved considerable gains year-to-date, supported by the high prosperity of their respective industries. Specifically, continued strength in international gold prices has driven the gold sector collectively higher, with Chifeng Gold gaining over 120% year-to-date. The new consumption track continues its momentum, with Laopu Gold becoming a market focus with gains exceeding 200%. The biopharmaceutical sector has also welcomed value revaluation, with innovative drugs, CXO, and medical device sub-sectors performing strongly, with multiple stocks doubling in price. Among them, RemeGen surged nearly 670% year-to-date, while 3SBIO's market value also broke through HK$77 billion.

Inclusion in international indices typically signifies broader capital attention and liquidity premiums. With passive fund allocations from index funds, companies are expected to receive more incremental funding, enhance trading activity, and provide additional stock price support. FTSE Russell's endorsement will also enhance their global market visibility and credibility, laying the foundation for attracting quality capital and expanding cooperation, facilitating long-term value realization.

Related Concept Stocks:

Chifeng Gold (06693): A mining company focused on gold mining and comprehensive resource recovery utilization. In the first half of 2025, the company's net profit attributable to shareholders soared to RMB 1.107 billion, a dramatic 55.79% year-on-year increase. Despite facing challenges such as rising production costs, under the backdrop of the Federal Reserve's rate-cutting cycle and overlapping geopolitical risks, the gold bull market pattern is expected to continue, making the company's earnings elasticity worth anticipating.

Laopu Gold (06181): Listed on the Hong Kong Stock Exchange on June 28, 2024, with stock prices soaring after listing, becoming the "new aristocrat" of the gold retail sector. Its stock price has cumulatively risen 204.65% year-to-date, while its performance since listing has been even more impressive, surging 17.14 times from the issue price, with stock prices exceeding Tencent Holdings to become the highest-priced stock in the Hong Kong market.

SF Intra-city (09699): As China's largest third-party instant delivery platform, SF Intra-city has seen steady growth in market value and liquidity since listing in December 2021. Leveraging its industry-scarce independent third-party positioning and full-scenario business model, it has become important infrastructure for instant retail development, with a solid industry leadership position. Daiwa recently issued a research report maintaining SF Intra-city's target price at HK$20, reiterating a "Buy" rating, and raising earnings per share forecasts for 2025-2027 by 6-7%, reflecting better-than-expected revenue prospects.

3SBIO (01530): A high-tech enterprise integrating biopharmaceutical R&D, production, and sales. In May this year, 3SBIO received market attention for its massive BD deal signed with Pfizer. Recent market value breakthrough of HK$77 billion marked a new high since listing, with year-to-date market value growth exceeding HK$63.5 billion.

Fourth Paradigm (06682): Recently, multiple renowned brokerages have raised Fourth Paradigm's target price, unanimously optimistic about this AI pioneer's growth potential and unique value in the "AI+" era. Bank of Communications International raised Fourth Paradigm's target price from HK$64 to HK$81, maintaining a "Buy" rating. Daiwa believes Fourth Paradigm's position in the artificial intelligence field is solid and expects it to benefit from the "AI+" development trend, raising the company's target price from HK$58 to HK$74.